{"auto_keywords": [{"score": 0.00481495049065317, "phrase": "registered_drugs"}, {"score": 0.004576253356889219, "phrase": "protease-activated_receptor"}, {"score": 0.004404994123834589, "phrase": "virtual_screening"}, {"score": 0.004240116703465252, "phrase": "drug_database"}, {"score": 0.004133627071344356, "phrase": "carvedilol"}, {"score": 0.0040298010803060495, "phrase": "loratadine"}, {"score": 0.003928572641266562, "phrase": "nefazodone"}, {"score": 0.003829877278269543, "phrase": "astemizole"}, {"score": 0.003593812067062062, "phrase": "ligand_docking_and_molecular_dynamics_simulations"}, {"score": 0.003245900020944865, "phrase": "putative_binding_mode"}, {"score": 0.002931569771634119, "phrase": "competitive_binding"}, {"score": 0.002785978280998868, "phrase": "calcium_mobilization"}, {"score": 0.0026140878612307536, "phrase": "transfected_cells"}, {"score": 0.0021593396036472777, "phrase": "gpcr_hit-finding"}, {"score": 0.0021049977753042253, "phrase": "fda-approved_drugs"}], "paper_keywords": [""], "paper_abstract": "Virtual screening of a drug database identified Carvedilol, Loratadine, Nefazodone and Astemizole as PAR2 antagonists, after ligand docking and molecular dynamics simulations using a PAR2 homology model and a putative binding mode of a known PAR2 ligand. The drugs demonstrated competitive binding and antagonism of calcium mobilization and ERK1/2 phosphorylation in CHO-hPAR2 transfected cells, while inhibiting IL-6 secretion in PAR2 expressing MDA-MB-231 breast cancer cells. This research highlights opportunities for GPCR hit-finding from FDA-approved drugs.", "paper_title": "Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2", "paper_id": "WOS:000363914200002"}